- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
AOM Infusion Selected as Limited Distribution Specialty Pharmacy for New Immune Globulin Therapy
QIVIGY® is a new 10% immune globulin liquid indicated for treatment of adults with Primary Humoral Immunodeficiency
Mar. 13, 2026 at 1:07pm
Got story updates? Submit your updates here. ›
AOM Infusion, a leading specialty infusion pharmacy, has joined Kedrion Biopharma's limited distribution network for QIVIGY®, a new 10% immune globulin (Ig) liquid indicated for the treatment of adults with Primary Humoral Immunodeficiency (PI). This addition expands AOM's immune globulin portfolio and strengthens its ability to help patients and providers access innovative therapies for complex immune disorders.
Why it matters
The partnership between AOM Infusion and Kedrion Biopharma aims to improve access to life-enhancing therapies for patients with complex immune disorders. By expanding its Ig portfolio with QIVIGY, AOM is strengthening its support for providers with reliable therapy options and helping patients receive high-quality infusion care.
The details
QIVIGY is a ready-to-use, sterile, non-pyrogenic liquid solution of human immune globulin (IgG) for IV administration. It supplies a broad spectrum of antibodies against bacterial and viral agents to support patients with Primary Immunodeficiency Disorders (PID). Kedrion selected AOM as a distribution partner for its deep expertise in immune globulin therapy, national reach, and patient-centered clinical model. AOM's recognition as one of the first specialty providers to earn the Distinction in Ig Therapy from the ACHC and IgNS further demonstrates its commitment to clinical excellence, patient safety, and outcomes-driven care.
- The partnership was announced on March 13, 2026.
The players
AOM Infusion
A nationally licensed infusion pharmacy with more than 30 years of experience delivering specialty infusion care to patients with complex, chronic conditions.
Kedrion Biopharma
A company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for rare, ultra-rare, and debilitating conditions.
QIVIGY
A new 10% immune globulin (Ig) liquid indicated for the treatment of adults with Primary Humoral Immunodeficiency (PI).
What they’re saying
“We're proud to make QIVIGY available nationwide, offering a reliable new option for patients in need of IVIG therapy.”
— Bob Rossilli, Chief Commercial Officer of Kedrion
“This partnership with Kedrion reflects our shared commitment to improving access to life-enhancing therapies for patients with complex immune disorders.”
— Karmen Stowe, Vice President of Trade Relations & Supply Chain at AOM Infusion
The takeaway
The partnership between AOM Infusion and Kedrion Biopharma demonstrates the importance of expanding access to innovative therapies for patients with complex immune disorders. By combining their expertise and resources, the companies aim to bring QIVIGY to more communities and support patients in receiving high-quality infusion care.
